- Capital Cube•8 days ago
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Exelixis, Inc. a score of 28. Our analysis is based on comparing Exelixis, Inc. with the following peers – Sanofi Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Johnson & Johnson, ArQule, Inc., Pfizer Inc., AVEO Pharmaceuticals, Inc. and Curis, ... Read more (Read more...)
- Motley Fool•9 days ago
Following Takeda's multibillion-dollar acquisition of cancer drugmaker Ariad Pharmaceuticals, Array Biopharma, Seattle Genetics, and Exelixis could be the next to be bought.
- Zacks•9 days ago
Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?
EXEL : Summary for Exelixis, Inc. - Yahoo Finance
Exelixis, Inc. (EXEL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Day's Range||17.79 - 18.23|
|52 Week Range||3.55 - 19.30|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-27.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|